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Objectives. We sought to investigate the cardiac effects of
growth hormone (GH) administration during the early phase of
pathologic remodeling in a rat model of large myocardial infarc-
tion (MI).
Background. Recent evidence suggests that exogenous admin-
istration of GH evokes a hypertrophic response and increases left
ventricular (LV) function in vivo in rats with normal or chroni-
cally failing hearts. We hypothesized that these effects would
attenuate ventricular remodeling early after MI.
Methods. Fifty-eight male rats underwent sham operation (n 5
19) or had induced MI (n 5 39). The day after the operation, the
infarcted rats were randomized to receive 3 weeks of treatment
with GH, 3 mg/kg body weight per day (n 5 19) or placebo (n 5
20). Echocardiography, catheterization and isolated whole heart
preparations were used to define cardiac structure and function.
Results. Growth hormone caused hypertrophy of the nonin-
farcted myocardium in a concentric pattern, as noted by higher
echocardiographic relative wall thickness at 3 weeks and by
morphometric histologic examination. Left ventricular dilation
was reduced in the GH-treated versus placebo group (echocardio-
graphic LV diastolic diameter to body weight ratio 2.9 6 0.1 vs.
3.5 6 0.2 cm/kg; p < 0.05). In vivo and in vitro cardiac function
was improved after GH treatment. Despite elevated insulin-like
growth factor-1 (IGF-1) serum levels in GH-treated rats, myocar-
dial IGF-1 messenger ribonucleic acid was not different among the
three groups, suggesting that an increase in its local expression
does not appear necessary to yield the observed effects.
Conclusions. These data demonstrate that early treatment of
large MI with GH attenuates the early pathologic LV remodeling
and improves LV function.
(J Am Coll Cardiol 1997;29:1109–16)
©1997 by the American College of Cardiology
Ischemic heart failure is thought to arise directly from the loss
of functioning myocardium due to myocardial infarction (MI)
and from many secondary processes that contribute to the
depression of left ventricular (LV) function. Chief among
these is pathologic remodeling, in which dilation and resultant
afterload excess combine to initiate a downward spiral of
deterioration in function, with subsequent hemodynamic and
neurohumoral adaptations to LV dysfunction (1,2). Prevention
or attenuation of these secondary processes is an important
therapeutic goal.
Recently, several studies have suggested that growth hor-
mone (GH) targets the heart (3–5) and may be of benefit in
chronic heart failure (6–8). In particular, two animal studies
have shown an improved hemodynamic profile after GH
administration in established heart failure due to MI (6,7).
These beneficial effects may be transferable to humans: GH
administration in seven patients with idiopathic dilated cardio-
myopathy resulted in improvement in hemodynamic variables,
myocardial energy metabolism and clinical status (8).
These earlier investigations focused on treatment of
chronic, well-established heart failure, studied when most of
the dynamic remodeling processes, including attendant gene
activation, LV dilation and hypertrophy of the noninfarcted
myocardium, have already occurred in the rat model used
(treatment begun 4 weeks and 3 months after MI) (1).
However, in reviewing the known effects of GH on the heart,
we postulated that it might also have salutary effects early after
MI, by attenuating remodeling and thereby preventing or
limiting the development of ischemic heart failure. Growth
hormone’s ability to induce concentric hypertrophy (9,10)
would reduce LV wall stress (11), and its effects on contractility
(9,12) would enhance the function of the noninfarcted myo-
cardium, both of which would be of particular benefit if applied
while the process of remodeling was beginning or ongoing.
Thus, in the current study, GH treatment was initiated 24 h
after coronary ligation in a well-established rat model of large
MI. A combined histologic, echocardiographic, high fidelity
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micromanometric and isolated whole heart approach was used
to define changes in structure and in vivo and in vitro function;
the paracrine/autocrine effects of GH were examined assessing
ventricular expression of insulin-like growth factor-1 (IGF-1)
messenger ribonucleic acid (mRNA).
Methods
All animal procedures were conducted in accordance with
the requirements of the American Physiological Society, and
confirm to the “Position of the American Heart Association on
Research Animal Use” adopted by the Association in Novem-
ber 1984. Myocardial infarction was induced according to
previously described methods (13). Briefly, male Sprague-
Dawley rats (Charles River Breeding Laboratories) with a
body weight ranging from 220 to 250 g, were anesthetized with
an intraperitoneal injection of pentobarbital (60 mg/kg body
weight) and orally intubated. After performing an anterior
thoracotomy, the heart was exteriorized and a 6-0 silk suture
was snugly placed around the proximal left anterior descending
coronary artery. Nineteen sham animals (sham group) under-
went the same operation, but did not receive the ligation of the
coronary artery. The perioperative mortality rate in the MI
group was ;50%. The day after the procedure all surviving
animals were screened by transthoracic echocardiography (see
later) for the presence of large infarctions involving at least
35% of the left ventricle; four rats were excluded because of
smaller infarct sizes. On the same postoperative day, after the
echocardiogram, the animals were randomized to receive GH
(n 5 19; 3 mg/kg per day of recombinant human GH through
two daily subcutaneous injections; MI-GH group) or placebo
(n 5 20; MI group) for 3 weeks. This treatment protocol was
designed based on our previous observations of a significant
hypertrophic response in vivo and increased cardiac function in
normal rats given a similar dose of GH for a similar treatment
period (9). The majority of the myocardial remodeling process
in the rat (70% to 80%) is complete within 3 weeks (1), and the
potential development of antibodies to human GH with longer
treatment is avoided. Recombinant human GH was provided
by Genentech, Inc.
Echocardiography. Transthoracic echocardiography was
performed in all animals before the operation (baseline echo-
cardiogram), 1 day after the operation (to ensure large MI in
all animals subsequently studied) and after 3 weeks of therapy.
Previous reports from our laboratory (9,13) and that of others
(14) have demonstrated the accuracy and reproducibility of
transthoracic echocardiography in rats. Briefly, rats were anes-
thetized with a combination of ketamine hydrochloride
50 mg/kg (Parke Davis) and xylazine 10 mg/kg intraperitone-
ally (Lloyd Laboratories) and placed on a specially designed
apparatus. Echocardiography was performed from underneath
with a Hewlett-Packard Sonos 1500 sector scanner equipped
with a 7.5-MHz phased-array transducer. Two-dimensionally
guided M-mode tracings were recorded with a strip-chart
recorder at a paper speed of 100 mm/s (Fig. 1). Posterior wall
thickness and LV internal dimensions were measured accord-
ing to the leading edge method of the American Society of
Echocardiography (15). Left ventricular outflow tract diameter
was measured on a still-frame two-dimensional image at the
base of the aortic leaflets in a parasternal long-axis view.
Infarct size was measured from the 3-week echocardiogram by
observing the akinetic region in real time and measuring the
percentage of the LV endocardial circumference that was
akinetic on a freeze-frame image at end-diastole, as previously
described (13). All measurements were performed by one
observer who had no knowledge of the previous results and
were based on the average of three consecutive cardiac cycles.
Two-dimensionally guided pulsed Doppler recordings of
LV inflow were obtained from the apical four-chamber view.
Doppler recordings were made at a paper speed of 100 mm/s
and analyzed off-line. Measurements were made from six
consecutive cycles to minimize beat to beat variability. Maxi-
mal early and late diastolic flow velocities were derived from
mitral inflow velocities, and LV outflow tract velocimetry was
recorded from a five-chamber view. Stroke volume was calcu-
lated as:
Abbreviations and Acronyms
ANOVA 5 analysis of variance
cDNA 5 complementary deoxyribonucleic acid
dP/dt 5 rate of rise of left ventricular pressure
GH 5 growth hormone
IGF-1 5 insulin-like growth factor-1
LV 5 left ventricular (ventricle)
MI 5 myocardial infarction
mRNA 5 messenger ribonucleic acid
Figure 1. Representative echocardiographic (top panels) and hemo-
dynamic (bottom panels) tracings obtained from rats given placebo
after myocardial infarction (MI-placebo) and rats treated with growth
hormone after myocardial infarction (MI-GH). Growth hormone–
treated animals showed hypertrophy and increased systolic thickening
of the noninfarcted posterior wall. Left ventricular end-diastolic
pressure was significantly lower and peak positive and peak negative
rate of rise of LV pressure (dP/dt) significantly higher after GH
treatment. Heart rate was similar in both tracings.
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Aortic velocity time integral 3 ~p@LV outflow tract/2#2!,
and multiplied by heart rate to calculate cardiac output. When
appropriate, structural and functional indexes were normalized
to body weight or tibial length, or both, because of the
considerable somatic growth in the MI-GH group.
Hemodynamic studies. Within 12 h of the final echocar-
diogram, the rats were anesthetized with ketamine and xyla-
zine at the same doses used for the earlier echocardiograms. A
calibrated 2F micromanometer-tipped catheter (Millar Instru-
ments) was passed through the carotid artery into the LV
under constant pressure monitoring. Left ventricular end-
diastolic pressure was recorded with an expanded scale and
rate of rise of LV pressure (dP/dt) was obtained from a
differentiating circuit in the physiologic recorder (model 2400,
Gould, Inc.). Because changes in LV shape and uniformity
after MI prevent the calculation of true LV wall stress from
monodimensional images, we devised an approximate measure
of load of the noninfarcted myocardium, termed posterior wall
load index, using the following formula (16):
0.334 3 LV pressure 3 ~LVID/@1 1 PWT/LVID#!,
where LVID is left ventricular internal diameter (end-systolic
or end-diastolic), and PWT is posterior wall thickness. Al-
though pressures and dimensions were measured under iden-
tical anesthetic conditions, they were not performed simulta-
neously. Nevertheless, we believe that additional useful
information could be derived from these data. An estimation
of vascular resistance was calculated as:
Mean arterial blood pressure/Cardiac output,
and normalized to body weight.
Isolated whole heart preparation. An additional subgroup
of 18 rats (six from each group) was killed, and the isolated
hearts were placed in an isovolumic, buffer-perfused rat heart
preparation according to the Langendorff technique, as previ-
ously described (12). After anesthetization, the hearts were
quickly removed and put into ice-cold Krebs-Henseleit solu-
tion (see later), weighed and mounted on a cannula inserted
into the ascending aorta. Retrograde aortic perfusion of the
coronary arteries was performed within 30 s through a constant
flow of 10 ml/min per g heart weight, and the pressure
monitored by a Statham P23Db transducer. Coronary flow in
the MI group was corrected for scar weight (16% of total heart
weight on average, assuming that perfusion of the scar is
minimal) (17,18). The composition of the perfusate was as
follows (mmol/liter): NaCl 118, KCl 4.7, KH2PO4 1.2, CaCl2
1.5, MgCl2 1.2, NaHCO3 23 and dextrose 5.5, saturated with a
95% oxygen/5% carbon dioxide gas mixture to a pH of 7.4 6
0.2. Left ventricular pressure was measured using a fluid-filled
latex balloon inserted through the mitral valve. After 15 to
30 min at 25°C, the temperature was gradually increased to
37°C and the hearts were paced at 4 Hz. Measurements of LV
function were obtained when the preparation achieved a
steady state after instrumentation (;15 min) at a common
diastolic pressure of 10 mm Hg. Both absolute values of
developed pressure and those normalized to LV wet weight
were assessed.
Postmortem studies. After catheterization, the animals
were randomly assigned to either RNA extraction and dot-blot
analysis (seven each from the MI and sham groups, and six
from the MI-GH group) or histologic examination (six from
each group). A subgroup of 18 animals (six per each treatment
group) underwent echocardiography and isolated whole heart
studies. Blood samples and tibial length measurements were
obtained from all animals.
Blood analysis. Duplicate hematocrit samples were pre-
pared in microhematocrit tubes. Serum was frozen at 220°C
for subsequent analysis. Human and rat GH was measured in
rat serum by enzyme-linked immunosorbent assay, and total
serum IGF-1 was measured by radioimmunoassay, according
to previously described methods (19,20).
Ribonucleic acid extraction and dot-blot analysis. Because
the effects of GH appear to be mediated in part by local
production of IGF-1 in target tissues (14), we measured the
ventricular level of IGF-1 mRNA by dot blotting. Immediately
after catheterization, the hearts were excised and the atria
trimmed, and the ventricular tissue was quickly dropped into
liquid nitrogen and stored at 270°C for subsequent analysis.
Total muscle RNA was extracted by the guanidinium
thiocyanate-phenol-chloroform method (22). A 40-mg aliquot
of total RNA per sample was denaturated and applied to nylon
membranes (Gene Screen Plus, Dupont, NEN Products) using
a dot-blot vacuum manifold apparatus (Scheider and Schuell).
After immobilization by ultraviolet cross-linking, the blots
were hybridized overnight at 42°C with phosphorus-32–labeled
IGF-1 complement deoxyribonucleic acid (cDNA) (Dr. P.
Rotwein, Washington University) or 18S ribosomal cDNA (Dr.
P. Bachierre, Centre de Recerche de Biochimie et Genetique
Cellulaires, Toulouse Cedex, France) and washed according to
methods described by the manufacturer of the nylon mem-
branes, and the intensity of labeling of individual dots was
quantitated with a Phosphorimager (Molecular Dynamics).
The 18S ribosomal cDNA probe was used to correct for total
RNA loading differences.
Histologic examination. Left ventricles were immersion
fixed in 10% buffered formalin. Four cross sections, cut from
apex to base, were embedded in paraffin and stained with
hematoxylin-eosin for measurements of muscle fiber diameter
and with Masson trichrome for assessment of interstitial
fibrosis. The four sections were then projected, and average
infarct size was estimated by measuring the percentage of the
total endocardial circumference replaced by scar tissue. Quan-
titative evaluation of myocyte hypertrophy was carried out by
morphometric analysis, according to previously described
methods (23), by an observer who had no knowledge of the
study protocol, on tissue blocks obtained from the nonin-
farcted interventricular septum. Briefly, each section was pro-
jected by using a binocular microscope (Zeiss, Germany)
attached to a video camera at 3400 magnification and a
personal computer (Apple Computer) equipped with morpho-
metric software. The circumferences of 100 myocytes per
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animal were digitized on each of the four sections, and average
myocyte area was calculated. Quantitative assessment of inter-
stitial tissue as a measure of fibrosis was accomplished with a
special grid on which horizontal and vertical lines provided 100
intersecting points, at 3400 magnification. Four fields on each
of the four sample sites were examined for each animal,
yielding a total of 16 fields in each rat. Reproducibility studies
showed a good correlation between data obtained from two
studies in four rats, for both techniques (r 5 0.90).
Tibial length. At the end of the experiment, the right hind
legs of the rats were removed by disarticulating the femurs
from the acetabula at the hip. The tibias were dissected free of
soft tissue and frozen at 220°C. Four radiographic films
(X-Omat XTL2, Eastman Kodak Company) of the tibias were
then obtained, and the tibial length of each animal was
measured on the radiograph with a caliper.
Statistical analysis. All data are given as mean value 6
SEM. Statistical analysis was performed using a Sun Microsys-
tem Station equipped with the PROPHET software package.
Intergroup comparisons of echocardiographic indexes were
performed using a two-way analysis of variance (ANOVA)
with repeated measures in one factor (time), followed by the
Neumann-Keuls test. One-way ANOVA was used for the other
comparisons, also followed by the Neumann-Keuls test. A
value of p , 0.05 was considered significant.
Results
Myocardial infarction in the absence of GH treatment
resulted in a lower average weight gain compared with the
sham group (4% vs. 11%). The MI-GH group exhibited a
weight gain of ;30% (Table 1), which was significantly greater
than that in the sham-operated control animals. Body weight
increase in the GH group followed a linear pattern (8% first
week, 9% second week and 13% third week vs. baseline
values), thereby demonstrating a continued effect of GH over
time. Tibial length was significantly increased in the GH-
treated animals as compared with the untreated rats. Hemat-
ocrit was not different among the three groups.
Rat GH levels were similar in all groups and, as expected,
human GH levels were undetectable in the sham and MI
groups and increased to ;2,000 ng/ml in GH-treated animals
(Table 1). Insulin-like growth factor-1 serum levels were also
significantly higher in the MI-GH group by ;30% to 35%.
Quantitation of total RNA by dot blotting showed no differ-
ences among the three study groups, when determined either
with or without correction for loading by measuring 18S RNA.
Histologic and echocardiographic infarct sizes were not
different between the untreated MI and MI-GH groups (Table
2). There was no evidence of fibrosis in either MI group.
Compared with the sham group, the untreated MI group
showed LV dilation, increased posterior wall thickness and
reduced systolic thickening of the noninfarcted posterior wall,
with a reduction of relative wall thickness and decreased
indexes of cardiac performance (Tables 3 and 4). Growth
hormone treatment oriented ventricular remodeling toward
greater functional advantage: there was significantly less cavity
dilation, less reduction in relative wall thickness and improve-
ment of all echocardiographic functional indexes (Fig. 1,
Tables 3 and 4). In vivo hemodynamic data substantiated the
beneficial effects of GH treatment on cardiac function: systolic
function was improved, as demonstrated by increased peak
positive dP/dt and by a blunted reduction of systolic and mean
arterial pressure after MI; diastolic function improved, as
shown by lower filling pressures and higher peak negative
dP/dt in the GH-treated group compared with the MI group
(Table 5). Because of the combined effects of GH treatment on
LV geometry and pressures, systolic and especially diastolic
load indexes of the noninfarcted LV posterior wall were both
significantly reduced in the MI-GH group compared with the
untreated MI group. The difference between the two infarcted
groups averaged 15% for systolic and 61% for diastolic load
index. An index of vascular resistance was slightly lower in
treated rats. At a common diastolic pressure of 10 mm Hg,
infarcted animals showed significantly lower values of devel-
oped pressure in the isolated whole heart than shams (Table
5). Furthermore, GH-treated animals had significantly higher
Table 1. Animal Characteristics and Hormone Determinations
Sham
Group
MI
Group
MI-GH
Group
Body weight (g)
Baseline 245 6 5 247 64 255 6 3
3 Weeks 273 6 4* 258 6 6 330 6 4*†‡
Tibial length (mm) 38.6 6 0.3 38.9 6 0.4 40.9 6 0.3†‡
Rat GH serum levels (ng/ml) 0.86 6 0.2 0.7 6 0.3 1.1 6 0.4
Human GH serum levels (ng/ml) Undetectable Undetectable 2,000 6 220
IGF-1 serum levels (ng/ml) 292 6 13 286 6 18 390 6 25†‡
IGF-1 mRNA ventricular levels
(arbitrary units)
100 6 3 96 6 3 109 6 10
Hematocrit (ml/dl) 51 6 10 50 6 10 49 6 10
*p , 0.05 versus baseline. †p , 0.05 versus sham group. ‡p , 0.05 versus myocardial infarction group. Data are
presented as mean value 6 SEM. GH 5 growth hormone; IGF-1 5 insulin-like growth factor-1; MI 5 placebo-treated
group with myocardial infarction; MI-GH 5 MI group treated with GH; mRNA 5 messenger ribonucleic acid.
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developed pressures than the untreated infarcted group, sug-
gesting that increased contractility of the noninfarcted LV wall
played an important role in the overall improved hemody-
namic profile documented in vivo. Although balloon volumes
tended to be higher in the infarcted groups, there were no
significant differences among the three groups (0.25 6 0.11,
0.36 6 0.12 and 0.35 6 0.9 ml in controls, placebo infarcted
and GH infarcted, respectively).
Discussion
This study demonstrates several beneficial effects of GH
treatment on the remodeling process in the well-established
model of large MI in the rat. There was a reduction of LV
dilation and an improvement of systolic and diastolic function.
Hypertrophy of the noninfarcted myocardium with GH was
documented both by histologic measures of myocyte area and
Table 2. Measures of Cardiac Tissue Response
Sham
Group
MI
Group
MI-GH
Group
Infarct size, by histology (%) — 47 6 3 48 6 4
Infarct size, by echocardiography (%) — 47 6 3 46 6 3
Myocyte area (mm2) 201 6 12 210 6 11 258 6 16†‡
Interstitial tissue (%) 5.0 6 0.3 4.7 6 0.2 5.3 6 0.3
LV wet weight (g) 0.67 6 0.02 0.70 6 0.06 0.75 6 0.08
LV wet/body weight (mg/g) 2.42 6 0.10 2.67 6 0.30 2.25 6 0.20
LV wet/tibial length (mg/mm) 1.73 6 0.04 1.80 6 0.07 1.83 6 0.11
RV wet weight (g) 0.18 6 0.02 0.32 6 0.04† 0.33 6 0.03†
RV wet/body weight (mg/g) 0.66 6 0.02 1.24 6 0.05† 1.04 6 0.04†‡
RV wet/tibial length (mg/mm) 0.47 6 0.01 0.82 6 0.02† 0.80 6 0.01†
*p , 0.05 versus baseline. †p , 0.05 versus sham group. ‡p , 0.05 versus myocardial infarction group. Data are
presented as mean value 6 SEM. LV 5 left ventricular; MI 5 placebo-treated group with myocardial infarction;
MI-GH 5 MI group treated with growth hormone; RV 5 right ventricular.
Table 3. Echocardiographic Data: Morphology
Sham
Group
MI
Group
MI-GH
Group
AW diastole (mm)
Baseline 1.4 6 0.05 1.3 6 0.02 1.3 6 0.01
3 Weeks 1.4 6 0.04 1.2 6 0.03† 1.2 6 0.03†
AW thickening (%)
Baseline 90 6 10 88 6 9 85 6 11
3 Weeks 85 6 11 9 6 8*† 8 6 8*†
PW diastole (mm)
Baseline 1.4 6 0.04 1.4 6 0.06 1.4 6 0.05
3 Weeks 1.4 6 0.04 1.6 6 0.03*† 1.9 6 0.01*†‡
PW thickening (%)
Baseline 82 6 8 90 6 7 85 6 7
3 Weeks 78 6 9 42 6 8*† 61 6 6*†‡
LV diastolic diameter (mm)
Baseline 6.7 6 0.2 7.1 6 0.1 6.8 6 0.3
3 Weeks 6.8 6 0.01 9.2 6 0.4*† 9.3 6 0.5*†
LV diastolic diameter/BW (cm/kg)
Baseline 2.6 6 0.1 2.8 6 0.3 2.6 6 0.2
3 Weeks 2.4 6 0.1 3.5 6 0.2*† 2.9 6 0.1*†‡
LV systolic diameter (mm)
Baseline 3.8 6 0.2 3.9 6 0.2 3.7 6 0.4
3 Weeks 3.7 6 0.2 7.3 6 0.3*† 6.8 6 0.2*†
LV systolic diameter/BW (cm/kg)
Baseline 1.53 6 0.1 1.57 6 0.2 1.46 6 0.1
3 Weeks 1.35 6 0.1 2.78 6 0.3*† 2.05 6 0.2*†‡
Relative wall thickness
Baseline 0.43 6 0.02 0.41 6 0.01 0.41 6 0.01
3 Weeks 0.43 6 0.01 0.34 6 0.01*† 0.38 6 0.01*†‡
*p , 0.05 versus baseline. †p , 0.05 versus sham group. ‡p , 0.05 versus myocardial infarction group. Data are
presented as mean value 6 SEM. AW 5 anterior wall; BW 5 body weight; LV 5 left ventricular; MI 5 placebo-treated
group with myocardial infarction; MI-GH 5 MI group treated with growth hormone; PW 5 posterior wall.
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by echocardiographic assessment of posterior wall thickness.
These changes, combined with smaller cavity sizes and lower
filling pressures, contributed to a reduced systolic and diastolic
load index of the noninfarcted posterior wall. An index of
vascular resistance was reduced. The results of the isolated
whole heart studies strongly suggest that a direct effect on
contractility also played a role in improving the hemodynamic
profile in vivo, independent of the loading conditions. The
dot-blotting data suggest that paracrine/autocrine IGF-1 ac-
tions are not important in mediating GH effects in this model
system.
Growth hormone and postinfarction ventricular remodel-
ing. We have recently demonstrated that the pathologic postin-
farction remodeling process can be tracked longitudinally with
transthoracic echocardiography in a rat model of large MI
showing: 1) progressive LV cavity dilation; 2) hypertrophy of
noninfarcted myocardium; 3) gradual development of regional
contractile dysfunction in surviving regions; and 4) abnormal-
ities of diastolic filling (13). The current study shows that GH
treatment has beneficial effects on every aspect of this process.
We propose that the following physiologic mechanisms are at
play:
1. Induction of additional hypertrophy of the noninfarcted
myocardium. This represents a means by which LV wall stress
can be reduced according to Laplace’s law (11,24), and previ-
ous clinical and molecular biology studies performed in hu-
mans and animals provide a solid background for this “trophic”
effect (3–5).
2. Reduced vascular resistance. This is another important
mechanism of load reduction and is in keeping with our
previous observations in normal rats (9) and normal humans
(25,26) subjected to GH excess, and to other reports in
experimental heart failure in rats (6,7). Although the mecha-
nism is still unclear, this vasodilatory effect might be mediated
by IGF-1, because IGF-1 has been shown to have the same
effect in the human forearm (27). Alternatively, a decrease in
adrenergic-mediated vasoconstriction due to the better overall
hemodynamic profile induced by GH treatment could in part
explain this finding.
3. Enhanced function of the surviving myocardium. The
hypothesis that GH can directly affect cardiac contractility is
supported by several in vitro studies documenting that GH
excess increases myofilament calcium sensitivity (12,28).
Table 4. Echocardiographic Data: Function
Sham
Group
MI
Group
MI-GH
Group
Heart rate (beats/min)
Baseline 248 6 9 260 6 14 255 6 9
3 Weeks 246 6 6 249 6 9 250 6 9
Stroke volume (ml)
Baseline 0.26 6 0.03 0.27 6 0.03 0.25 6 0.03
3 Weeks 0.28 6 0.02 0.19 6 0.01*† 0.29 6 0.02‡
Stroke volume/BW (ml/kg)
Baseline 1.05 6 0.03 1.09 6 0.03 0.98 6 0.04
3 Weeks 1.03 6 0.04 0.72 6 0.03*† 0.89 6 0.03*†‡
Stroke volume/TL, 3 weeks
(ml/dm)
0.72 6 0.02 0.49 6 0.04† 0.71 6 0.04‡
LV fractional shortening (%)
Baseline 43 6 3 45 6 2 45 6 3
3 Weeks 44 6 2 19 6 3*† 28 6 2*†‡
Cardiac output (ml/min)
Baseline 65 6 5 70 6 4 64 6 5
3 Weeks 69 6 6 48 6 5*† 73 6 4‡
Cardiac output/BW (ml/kg)
Baseline 257 6 10 278 6 13 250 6 12
3 Weeks 255 6 8 185 6 11*† 220 6 13†‡
Cardiac output/TL, 3 weeks
(ml/dm)
177 6 7 122 6 8† 178 6 9‡
Mitral-E/A ratio
Baseline 2.2 6 0.16 2.1 6 0.14 2.0 6 0.14
3 Weeks 2.4 6 0.18 13.1 6 2*† 6.6 6 1*†‡
*p , 0.05 versus baseline. †p , 0.05 versus sham group. ‡p , 0.05 versus
myocardial infarction group. Data are presented as mean value 6 SEM. E/A 5
early transmitral flow velocity to atrial flow velocity ratio; TL 5 tibial length.
Other abbreviations as in Table 3.
Table 5. In Vivo Hemodynamic and In Vitro Whole-Heart Indexes of Cardiac Function
Sham
Group
MI
Group
MI-GH
Group
LV systolic blood pressure (mm Hg) 115 6 3 72 6 5* 80 6 4*
Mean aortic blood pressure (mm Hg) 95 6 3 66 6 4* 74 6 4*
LV end-diastolic pressure (mm Hg) 3.0 6 0.2 24 6 2* 11 6 2*†
Peak positive dP/dt (mm Hg/s) 7,900 6 340 3,000 6 120* 5,500 6 140*†
Peak negative dP/dt (mm Hg/s) 5,800 6 290 2,300 6 200* 3,100 6 300*†
Systemic vascular resistance (mm Hg/ml per
min per kg body weight)
0.38 6 0.01 0.37 6 0.01 0.32 6 0.02*†
Posterior wall systolic load index (kdyne/cm2) 80 6 5 101 6 7* 86 6 4†
Posterior wall diastolic load index (kdyne/cm2) 5.6 6 2 54 6 5* 21 6 4*†
Developed pressure in vitro (mm Hg) 108 6 8 54 6 5* 70 6 7*†
Normalized developed pressure in vitro
(mm Hg/g)
163 6 13 77 6 8* 93 6 6*†
Coronary perfusion pressure in vitro (mm Hg) 77 6 4 98 6 4* 93 6 3*
*p , 0.05 versus sham group. †p , 0.05 versus myocardial infarction group. Data are presented as mean value 6
SEM. dP/dt 5 rate of rise of left ventricular pressure. Other abbreviations as in Table 3.
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4. Beneficial effects of GH treatment on diastolic filling.
Reduced LV filling pressures, documented by noninvasive and
invasive techniques, are in keeping with our previous in vivo
observation that relaxation, as assessed by tau, is enhanced
after GH treatment in normal rats (9) and by the reduction of
the Doppler-detected isovolumic relaxation time observed in
patients with heart failure treated with GH (8). It is conceiv-
able that enhancement of systolic performance by GH might
facilitate LV emptying and thereby reduce LV filling pressures
(8,9). Alternatively, a direct effect of GH on relaxation or on
LV stiffness, or both, is also possible. Further research is
needed to clarify this issue.
Taken together, the combined and synergistic effects of GH
on myocardial growth, contractility and loading conditions are
precisely those which would be predicted to be of benefit given
our current understanding of the early remodeling process.
Growth hormone–induced hypertrophy. Although the hy-
pertrophy produced by GH treatment could be detrimental,
the preservation of capillary density (29), lack of fibrosis and
improvement in diastolic filling (present study, 8,9,30,31) all
suggest that GH excess results in a more physiologic rather
than pathologic form of hypertrophy. However, this and pre-
vious studies (6) concur that GH does not increase overall LV
weight in this MI model. This apparent paradox may be
explained by the balance between the prevention of LV
dilation and the induction of posterior wall hypertrophy.
To date, few studies have addressed whether additional
hypertrophy can be beneficial in the setting of postinfarction
remodeling. Litwin et al. (32) demonstrated beneficial effects
of LV hypertrophy induced by an inhibitor of long-chain fatty
acid oxidation or by L-thyroxine (33), although both therapies
have little clinical applicability.
A report by Duerr et al. (34) recently found that IGF-1,
given in the early phase of postinfarction remodeling in the rat,
induced a hypertrophic response and increased stroke volume
(normalized to tibial length). However, ejection fraction did
not change, and LV diastolic volumes increased after IGF-1
treatment when compared with no treatment. Although Duerr
et al. (34) did not examine cardiac geometry in vivo, it is likely
that the modification of remodeling was less striking with
IGF-1 than that observed with GH in our study because of
intrinsic differences in the actions of these two hormones
(9,21). In fact, in addition to opposite effects on glucose
metabolism, the hormones have differential effects in several
peripheral tissues, including the heart (9). Cardiac volumes
tended to be lower after GH rather than higher as reported
after IGF-1 (9,34), an important advantage of GH in reducing
load and attenuating remodeling. Furthermore, in the study by
Duerr et al., the rats’ smaller average MI size (26% vs. 47% in
our study) and the initiation of treatment on the second day
after infarction (rather than on the first day) might both have
contributed to the lesser effects of IGF-1.
Other investigators have confirmed a beneficial effect of
GH in the chronic phase of ischemic heart failure. Yang et al.
(6) reported that GH reduced LV filling pressures and periph-
eral vascular resistance and increased cardiac index in rats 4
weeks after MI. Jin et al. (7), using rats 3 months after MI,
demonstrated that the beneficial hemodynamic effects of com-
bined administration of GH and IGF-1 were additive to those
induced by captopril, although captopril’s effects in reducing
LV weight were still evident (7). The design for these studies
differs from the present one, as they (6,7) attempted to modify
function in well-established heart failure and not the early
remodeling process. Further, no in vivo assessment of LV
geometry, or in vitro assessment of function, was provided by
these earlier studies.
Growth hormone effects on serum and cardiac IGF-1 levels.
Although serum IGF-1 levels were significantly increased after
3 weeks of GH treatment, ventricular levels of IGF-1 mRNA
were not different among the three study groups. Thus, in-
creased local production of IGF-1 does not appear to have a
role in the observed cardiovascular effects of GH. In this model
system, IGF-1 may function predominantly as an endocrine
hormone rather than as a paracrine or autocrine growth factor,
a hypothesis supported by previous studies (35). Alternatively,
it is also conceivable that, given the presence of GH receptors
in the heart (36) and the demonstration of direct GH effects on
several tissues such as the growth plate (37), the reported
cardiovascular effects might be accounted for by direct cardiac
actions of GH. Because IGF-1 and IGF-1 receptor mRNA
have recently been demonstrated to be upregulated in viable
right and left ventricular myocytes 2 days after MI (38), it is
possible that local IGF-1 production has an important role
early in the post-MI period and then diminishes in the late
phase of remodeling.
Study limitations. Data are presented unnormalized as
well as normalized to both body weight and tibial length. This
was done because it has been suggested that tibial length is
more related to lean body mass than to total body weight (39).
We (9) and others (6,34) have used these normalization
methods in similar model systems.
Although it is not ideal to assess pressures under anesthe-
sia, all animal groups were consistently handled, thereby
supporting the validity of intergroup differences. Similarly, in
devising a posterior wall load index and estimating peripheral
resistance, we acknowledge the difficulty in obtaining in vivo
measures of regional mechanics and hemodynamic data in the
rat, and we specifically avoid the implication that we can
accurately assess either variable. We also did not evaluate the
entire Frank-Starling relation using full pressure volume curves.
Postmortem changes, fixation and processing are known to
cause dimensional alterations in tissues. It was assumed that
these changes should affect all hearts in a similar manner.
Thus, examination of general similarities and relative differ-
ences between the groups should be valid. Histologic measures
in this study did not include cell length and cell number, both
affected by remodeling (40) and GH administration.
Clinical implications. Considering that LV dysfunction
due to ischemic heart disease is the leading cause of congestive
heart failure in the United States, and that few effective drugs
are available, our findings may have substantial clinical impli-
cations. Among the most appealing aspects of GH is its ability
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to beneficially affect several of the pathologic compensatory
processes that follow large MI, especially the early remodeling
process, something few treatment strategies designed to re-
duce postinfarction heart failure are able to modify. Thus, in
strategies to reduce ischemia or heart failure, GH may occupy
a unique niche temporally located between efforts to reduce
direct injury related to infarct size (thrombolysis, primary
angioplasty) and longer term maintenance therapies that mod-
ulate neurohumoral, hemodynamic and arrhythmic conse-
quences of infarction, such as angiotensin-converting enzyme
inhibitors and beta-blockers. Although it is tempting to postu-
late that GH may play a “preventive” rather than a palliative
role in the treatment of postinfarction heart failure, further
definition of its effects and benefits will be necessary.
We are grateful to Dr. Luigi Sacca` for his helpful comments and suggestions.
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